Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, AL.
Psychiatric and Neurodevelopmental Genetics Unit, Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.
Diabetes. 2024 Jun 1;73(6):993-1001. doi: 10.2337/db23-0232.
African Americans (AAs) have been underrepresented in polygenic risk score (PRS) studies. Here, we integrated genome-wide data from multiple observational studies on type 2 diabetes (T2D), encompassing a total of 101,987 AAs, to train and optimize an AA-focused T2D PRS (PRSAA), using a Bayesian polygenic modeling method. We further tested the score in three independent studies with a total of 7,275 AAs and compared the PRSAA with other published scores. Results show that a 1-SD increase in the PRSAA was associated with 40-60% increase in the odds of T2D (odds ratio [OR] 1.60, 95% CI 1.37-1.88; OR 1.40, 95% CI 1.16-1.70; and OR 1.45, 95% CI 1.30-1.62) across three testing cohorts. These models captured 1.0-2.6% of the variance (R2) in T2D on the liability scale. The positive predictive values for three calculated score thresholds (the top 2%, 5%, and 10%) ranged from 14 to 35%. The PRSAA, in general, performed similarly to existing T2D PRS. The need remains for larger data sets to continue to evaluate the utility of within-ancestry scores in the AA population.
非裔美国人(African Americans,AAs)在多基因风险评分(polygenic risk score,PRS)研究中代表性不足。在这里,我们整合了来自多个关于 2 型糖尿病(type 2 diabetes,T2D)的观察性研究的全基因组数据,这些研究共纳入了 101987 名 AAs,使用贝叶斯多基因建模方法来训练和优化针对 AAs 的 T2D PRS(PRSAA)。我们进一步在三个独立的研究中对该评分进行了测试,这些研究共纳入了 7275 名 AAs,并将 PRSAA 与其他已发表的评分进行了比较。结果表明,PRSAA 每增加 1 个标准差,T2D 的患病风险就会增加 40-60%(优势比[odds ratio,OR] 1.60,95%置信区间[confidence interval,CI] 1.37-1.88;OR 1.40,95% CI 1.16-1.70;OR 1.45,95% CI 1.30-1.62),这在三个测试队列中均得到了验证。这些模型在患病倾向的尺度上捕获了 1.0-2.6%的 T2D 变异(R2)。根据三个计算得到的评分阈值(前 2%、5%和 10%)计算的阳性预测值范围在 14%至 35%之间。PRSAA 总体上与现有的 T2D PRS 表现相当。需要更大的数据集来继续评估在 AAs 人群中基于血统的评分的实用性。